

MD MEDICAL GROUP OPENS NEW CLINIC IN MOSCOW

21 June 2016, Moscow. MD Medical Group Investments Plc (“MD Medical Group”, “MDMG” or the “Company” – LSE:MDMG), a leading Russian private healthcare provider, announces that it has opened a new clinic, Mother and Child Khodynskoe Pole.

The new clinic, which has an area of 465 sqm, will offer a wide range of women’s healthcare services, including IVF, ultrasound, minor gynaecological procedures, consultations with geneticists and OBGYNs, as well as services in foetal medicine including foetal diagnostics and treatment. Other specialists on-site include endocrinologists, urologists, andrologists, ophthalmologists, and more.

Mother and Child Khodynskoe Pole has capacity for up to 300 minor gynaecological procedures, 1,000 IVF cycles, and 39,600 consultations with doctors each year.

Mother and Child Khodynskoe Pole operates to MD Medical Group’s high standards of medical care and is fitted with world-class equipment. This facility is the first clinic of its kind, and covers north and north-west of Moscow, which enables it to serve a higher volume of patients.

The total volume of investment in this project amounted to 75 million roubles.

In parallel with opening of the new clinic, the Group has decided to close its Mother and Child Sokol clinic, which had an area of 150 sqm and opened in 1996.

Mark Kurtser, CEO of MD Medical Group, said:

“Today we have opened another high-tech clinic in Moscow, a market we know well and one in which we see substantial potential for further development thanks to significant demand for the high-quality medical services that we provide. At this new clinic our focus will, as ever, be on women’s and the next generation’s healthcare, while also offering services to other family members.

“We are not only expanding our capacity, but also implementing a qualitative transformation, setting a high standard for the sector, and making high-tech medical care more accessible to a greater number of people. Our Mother and Child Khodynskoe Pole clinic will also further strengthen our position as a leader in reproductive medicine in Russia, thanks to its IVF department with a capacity of up to 1,000 cycles per year.”

For further information please contact:

Investors

Media

Elena Romanova
MD Medical Group Investments Plc

Tel: +7 495 331 4120
e.romanova@mcclinics.ru

EM

Tom Blackwell / Sergii Pershyn

Tel: +7 919 102 9064

MDMG@em-comms.com

About MD Medical Group

MD Medical Group operates in the highly attractive Russian private healthcare service market and has a leading position in high-quality women's health and paediatrics. The company manages 30 modern healthcare facilities, including 4 hospitals and 26 outpatient clinics in Moscow, St. Petersburg, Ufa, Perm, Samara and Samara region, Irkutsk, Novosibirsk, Irkutsk, Yaroslavl, Ryazan, Kostroma, Novokuznetsk, Krasnoyarsk, Omsk, and Barnaul.

The Company's shares have been listed on the London Stock Exchange (LSE ticker "MDMG") in the form of Global Depositary Receipts (GDRs) since 12 October 2012.

Forward-Looking Statements:

This press release contains forward looking statements, which are based on the Company's current expectations and assumptions and may involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. The forward looking statements contained in this press release are based on past trends or activities and should not be taken that such trends or activities will continue in the future. It is believed that the expectations reflected in these statements are reasonable, but they may be affected by a number of variables which could cause actual results or trends to differ materially, including, but not limited to: conditions in the market, market position of the Company, earnings, financial position, cash flows, return on capital and operating margins, anticipated investments and economic conditions; the Company's ability to obtain capital/additional finance; a reduction in demand by customers; an increase in competition; an unexpected decline in revenue or profitability; legislative, fiscal and regulatory developments, including, but not limited to, changes in environmental and health and safety regulations; exchange rate fluctuations; retention of senior management; the maintenance of labour relations; fluctuations in the cost of input costs; and operating and financial restrictions as a result of financing arrangements.

No statement in this press release is intended to constitute a profit forecast, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for the Company. Each forward looking statement relates only as of the date of the particular statement.